Antibacterial Activity of Boswellia carterii Aqueous Extract and Its Effect on Phagocytosis in vitro.

Boswellia serrate has been traditionally used for the treatment of several inflammatory diseases, and bacterial resistance to antibiotics has recently increased the use of bioproducts. The present study aimed to assess the antibacterial effect and phagocytic ability of the aqueous extract of the Boswellia serrata in bacteria isolated in nosocomial infections. Boswellia carterii plant was collected and prepared from the aqueous extract in different concentrations. A total of 125 samples were collected from various clinical sources, including urine, sputum, wounds, otitis, and blood, from patients of both genders in different age groups. The results demonstrated that out of the 59 infected samples, urine samples had the highest infection (68%), followed by wounds, sputum, and otitis reported as (60%), (44%), and (40%), respectively. On the other hand, blood samples had the lowest percentage of infection (28%). Microscopic diagnostic results, biochemical tests, API Staph System, API 20E System, and Vitek 2 Compact pointed out that the highest infection rates were related to Staphylococcus aureus (32.20%), Pseudomonas aeruginosa (25.33%), and Escherichia coli (22.03%), while the lowest infection rate was detected in Klebsiella pneumonia (20.33%). The results indicated that aqueous extract of Boswellia carterii had an antibacterial activity for all bacterial isolates, 25 mg/ml of extract gave an inhibition zone of 10.8 mm,10.4 mm, 7mm, and 10mm for S. aureus, E. coli, P aeruginosa, and K. pneumonia, respectively, while 200 mg/ml of extract gave 24 mm, 22 mm, 18.4 mm, and 20 mm, respectively. The results pointed to a significant increase in the phagocytosis rate, with the phagocytosis of blood samples treated with Boswellia carterii extract (79.7%), as compared to control samples (57.75%). As evidenced by the results of this study, the aqueous extract of the Boswellia carterii plant showed antibacterial effects and a positive impact on the phagocytic ratio; nonetheless, it is recommended that further studies be conducted to characterize the compounds of this herb.

Effects of Vitamin D on Risks and Severity of COVID-19 Infection.

In the last two decades, numerous studies have been carried out to find correlations between vitamin D and the efficiency of the lungs and respiratory system. This study aimed to find the relationship of taking vitamin D with the risks of the severity of infection with coronavirus disease 2019 (COVID-19) and the risk of infection of patients with chronic diseases. A total of 100 COVID-19 patients (61 males and 39 females) were included in the study and divided into groups, namely never taken vitamin D and taken a dose of 50 and 1,000 IU. The effects of gender, chronic diseases (i.e., hypertension and diabetes), and requiring intensive care unit (ICU) were evaluated. The results showed that females were at lower risks of infection with COVID-19 than males and taking 50 IU of vitamin D could lower the severe cases by 33%. It was also revealed that patients with chronic disease were more sensitive to COVID-19 and administering 50 units of vitamin D in these patients decreased the need for ICU from 49% to 9%. Given that vitamin D enhances the immune system and respiratory function, the findings of this research indicated that vitamin D reduced the risk of COVID-19; however, it was not able to prevent it.